{"id":72169,"date":"2026-08-10T13:22:27","date_gmt":"2026-08-10T05:22:27","guid":{"rendered":"https:\/\/flcube.com\/?p=72169"},"modified":"2026-08-10T13:22:28","modified_gmt":"2026-08-10T05:22:28","slug":"genfleet-therapeutics-initiates-phase-3-trial-of-gfh375-for-kras-g12d-mutant-nsclc-in-china-first-patient-enrolled","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72169","title":{"rendered":"GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D\u2011Mutant NSCLC in China, First Patient Enrolled"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>GenFleet Therapeutics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2595:HKG\">HKG: 2595<\/a>) announced that <strong>&#8220;Kylin\u2011Flight 01,&#8221;<\/strong> the registrational <strong>Phase 3 clinical trial<\/strong> of <strong>GFH375<\/strong> as monotherapy for <strong>non\u2011small cell lung cancer (NSCLC)<\/strong>, has been initiated in China with the <strong>first patient successfully enrolled<\/strong>. The milestone marks another step in GenFleet&#8217;s clinical advancement of its lead <strong>KRAS G12D inhibitor<\/strong> across multiple tumor types.<\/p>\n\n\n\n<h2 id=\"h-trial-overview\" class=\"wp-block-heading\">Trial Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Name<\/strong><\/td><td>Kylin\u2011Flight 01<\/td><\/tr><tr><td><strong>Phase<\/strong><\/td><td>Registrational Phase 3<\/td><\/tr><tr><td><strong>Treatment<\/strong><\/td><td>GFH375 monotherapy<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>KRAS G12D\u2011mutant non\u2011small cell lung cancer (NSCLC)<\/td><\/tr><tr><td><strong>Region<\/strong><\/td><td>China<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>Initiated; first patient enrolled<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>GFH375<\/strong>, an <strong>orally administered KRAS G12D inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Non\u2011covalently binds the <strong>KRAS G12D protein<\/strong>, inhibiting its interaction with downstream effector proteins; this disrupts persistent activation of downstream signaling pathways driven by KRAS G12D, ultimately achieving potent inhibition of tumor cell proliferation.<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> KRAS G12D is one of the most common yet historically difficult\u2011to\u2011target KRAS mutations, making oral, non\u2011covalent inhibition a notable mechanistic approach in precision oncology.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-pipeline-amp-regulatory-designations\" class=\"wp-block-heading\">Clinical Pipeline &amp; Regulatory Designations<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Program<\/th><th>Indication<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Kylin\u2011Flight 01<\/strong><\/td><td>KRAS G12D\u2011mutant NSCLC<\/td><td>Phase 3 initiated (first patient enrolled)<\/td><\/tr><tr><td><strong>Kylin\u2011Wings 01<\/strong><\/td><td>Pancreatic cancer<\/td><td>Registrational Phase 3 (already underway)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Breakthrough Therapy Designation (BTD):<\/strong> GFH375 monotherapy has received BTD for both <strong>KRAS G12D\u2011mutant NSCLC<\/strong> and <strong>pancreatic cancer<\/strong>, underscoring the potential of the asset in high\u2011unmet\u2011need indications.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-partnership-amp-commercial-rights\" class=\"wp-block-heading\">Partnership &amp; Commercial Rights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Rights Holder<\/th><th>Development Code<\/th><\/tr><\/thead><tbody><tr><td><strong>Outside China<\/strong><\/td><td><strong>Verastem<\/strong><\/td><td>VS\u20117375<\/td><\/tr><tr><td><strong>Within China<\/strong><\/td><td><strong>GenFleet Therapeutics<\/strong><\/td><td>GFH375<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">GenFleet has granted <strong>Verastem<\/strong> the rights to develop and commercialize GFH375 outside of China, while GenFleet retains all rights within China \u2014 a structure that splits global commercial exposure between the two companies.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>KRAS G12D Race:<\/strong> The initiation of a second registrational Phase 3 study positions GFH375 among the most clinically advanced KRAS G12D inhibitors, an area of intense competition and investor interest following early KRAS G12C successes.<\/li>\n\n\n\n<li><strong>Regulatory Momentum:<\/strong> Dual Breakthrough Therapy Designations in NSCLC and pancreatic cancer may support expedited review pathways in both indications.<\/li>\n\n\n\n<li><strong>Pipeline Breadth:<\/strong> Parallel Phase 3 programs in lung and pancreatic cancer broaden the asset&#8217;s commercial optionality across two of the most lethal solid tumors harboring KRAS G12D mutations.<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> The Verastem partnership provides a development and commercialization pathway outside China, while GenFleet retains full upside in its home market.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the clinical development, regulatory outcomes, and commercialization of GFH375 (VS\u20117375). Actual results may differ due to risks including clinical trial results, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026081000038_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026081000038_c.\"><\/object><a id=\"wp-block-file--media-5c37a156-33af-4a01-8402-c082f6ab7a27\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026081000038_c.pdf\">2026081000038_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026081000038_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5c37a156-33af-4a01-8402-c082f6ab7a27\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GenFleet Therapeutics (HKG: 2595) announced that &#8220;Kylin\u2011Flight 01,&#8221; the registrational Phase 3 clinical trial of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,1682,4345],"class_list":["post-72169","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-genfleet-therapeutics","tag-hkg-2595"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D\u2011Mutant NSCLC in China, First Patient Enrolled - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GenFleet Therapeutics (HKG: 2595) announced that &quot;Kylin\u2011Flight 01,&quot; the registrational Phase 3 clinical trial of GFH375 as monotherapy for non\u2011small cell lung cancer (NSCLC), has been initiated in China with the first patient successfully enrolled. The milestone marks another step in GenFleet&#039;s clinical advancement of its lead KRAS G12D inhibitor across multiple tumor types.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72169\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D\u2011Mutant NSCLC in China, First Patient Enrolled\" \/>\n<meta property=\"og:description\" content=\"GenFleet Therapeutics (HKG: 2595) announced that &quot;Kylin\u2011Flight 01,&quot; the registrational Phase 3 clinical trial of GFH375 as monotherapy for non\u2011small cell lung cancer (NSCLC), has been initiated in China with the first patient successfully enrolled. The milestone marks another step in GenFleet&#039;s clinical advancement of its lead KRAS G12D inhibitor across multiple tumor types.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72169\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T05:22:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T05:22:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72169#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72169\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D\u2011Mutant NSCLC in China, First Patient Enrolled\",\"datePublished\":\"2026-08-10T05:22:27+00:00\",\"dateModified\":\"2026-08-10T05:22:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72169\"},\"wordCount\":447,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"GenFleet Therapeutics\",\"HKG: 2595\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72169#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72169\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72169\",\"name\":\"GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D\u2011Mutant NSCLC in China, First Patient Enrolled - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-10T05:22:27+00:00\",\"dateModified\":\"2026-08-10T05:22:28+00:00\",\"description\":\"GenFleet Therapeutics (HKG: 2595) announced that \\\"Kylin\u2011Flight 01,\\\" the registrational Phase 3 clinical trial of GFH375 as monotherapy for non\u2011small cell lung cancer (NSCLC), has been initiated in China with the first patient successfully enrolled. The milestone marks another step in GenFleet's clinical advancement of its lead KRAS G12D inhibitor across multiple tumor types.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72169#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72169\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72169#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D\u2011Mutant NSCLC in China, First Patient Enrolled\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D\u2011Mutant NSCLC in China, First Patient Enrolled - Insight, China&#039;s Pharmaceutical Industry","description":"GenFleet Therapeutics (HKG: 2595) announced that \"Kylin\u2011Flight 01,\" the registrational Phase 3 clinical trial of GFH375 as monotherapy for non\u2011small cell lung cancer (NSCLC), has been initiated in China with the first patient successfully enrolled. The milestone marks another step in GenFleet's clinical advancement of its lead KRAS G12D inhibitor across multiple tumor types.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72169","og_locale":"en_US","og_type":"article","og_title":"GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D\u2011Mutant NSCLC in China, First Patient Enrolled","og_description":"GenFleet Therapeutics (HKG: 2595) announced that \"Kylin\u2011Flight 01,\" the registrational Phase 3 clinical trial of GFH375 as monotherapy for non\u2011small cell lung cancer (NSCLC), has been initiated in China with the first patient successfully enrolled. The milestone marks another step in GenFleet's clinical advancement of its lead KRAS G12D inhibitor across multiple tumor types.","og_url":"https:\/\/flcube.com\/?p=72169","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-10T05:22:27+00:00","article_modified_time":"2026-08-10T05:22:28+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72169#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72169"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D\u2011Mutant NSCLC in China, First Patient Enrolled","datePublished":"2026-08-10T05:22:27+00:00","dateModified":"2026-08-10T05:22:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72169"},"wordCount":447,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","GenFleet Therapeutics","HKG: 2595"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72169#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72169","url":"https:\/\/flcube.com\/?p=72169","name":"GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D\u2011Mutant NSCLC in China, First Patient Enrolled - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-10T05:22:27+00:00","dateModified":"2026-08-10T05:22:28+00:00","description":"GenFleet Therapeutics (HKG: 2595) announced that \"Kylin\u2011Flight 01,\" the registrational Phase 3 clinical trial of GFH375 as monotherapy for non\u2011small cell lung cancer (NSCLC), has been initiated in China with the first patient successfully enrolled. The milestone marks another step in GenFleet's clinical advancement of its lead KRAS G12D inhibitor across multiple tumor types.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72169#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72169"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72169#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D\u2011Mutant NSCLC in China, First Patient Enrolled"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72169"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72169\/revisions"}],"predecessor-version":[{"id":72171,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72169\/revisions\/72171"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}